This presentation from the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago earlier this week, reviews the evidence for the efficacy of immunotherapy combinations for the treatment of metastatic renal cell carcinoma (RCC).
The authors concluded that immunotherapy-VEGF inhibitor combinations have similar effectiveness as combinations of immunotherapy drugs, and there does not seem to be a superior first-line immunotherapy combination for use in metastatic RCC. The authors also looked at second-line treatments, which were mostly VEGF inhibitors. Second-line response rates were greater in those who received immunotherapy combinations initially, although there was no difference in second-line time to treatment failure compared to VEGF inhibitors. Lastly, the use of immunotherapy combinations following first-line treatment with immunotherapy-VEGF inhibitor combinations was uncommon.